Nomura Phase4 Ventures

Overview

Nomura Phase4 Ventures (NPV) is a London-based specialist investment unit of Nomura, the Japanese financial services group. NPV, formerly Nomura’s BioPharma Private Equity Group, has been investing since 1998. It invests primarily in mid- to late-stage private companies from the biopharmaceuticals, specialty pharmaceuticals, and medical devices sectors in North America and Europe. NPV is currently investing through the Nomura Phase4 Ventures LP fund. The NPV team’s investment expertise is leveraged further by working closely with a number of senior advisors with extensive operating experience in pharmaceutical and biotechnology companies. NPV's investment strategy focuses on identifying and supporting companies with strong growth potential in the healthcare sector. The firm has a history of successful investments, including the spin-out of Albireo Pharma from AstraZeneca, which led to the development of novel therapies for gastrointestinal diseases. Additionally, NPV has been involved in financing companies like OncoMed Pharmaceuticals, which specializes in cancer stem cell research, and Phenomix Corporation, a drug discovery and development company targeting major human diseases. These investments highlight NPV's commitment to advancing healthcare through strategic partnerships and funding. The firm's portfolio reflects a diverse approach within the healthcare industry, encompassing areas such as biopharmaceuticals, specialty pharmaceuticals, and medical devices. NPV's focus on mid- to late-stage companies allows it to provide substantial capital and strategic guidance to businesses poised for significant growth. By leveraging its extensive network and expertise, NPV aims to drive innovation and deliver value to both its portfolio companies and investors.